Sep 19, 2008 - Maxygen, Inc. (Nasdaq:MAXY) and Astellas Pharma Inc. today announced a global agreement under which Astellas will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection.
The details can be read here.
No comments:
Post a Comment